[Clinical evaluation of cefotiam in adults urinary tract infections (author's transl)].
Cefotiam, a new broad-spectrum cephalosporin was used for the treatment of 30 cases of urinary-tract infections (UTI). Patients, 20 females, 10 males were between 23 and 76 years old. UTI were 17 cystitis, 9 pyelonephritis and 4 prostatitis. Bacteria isolated from urine were : 24 E. Coli, 3 Proteus mirabilis, 1 Providencia, 3 Klebsiella, 3 Enterobacter, 2 Serratia, 1 Staphylococcus coagulase--, DNAse--. MIC's of cefotiam ranged from 0.003 to 32 micrograms/ml (median MIC : 0.06 microgram/ml). Cefotiam was given intramuscularly in monotherapy, at the daily dosage of 1 and 2 g in two injections during 7 to 28 days. Followup of patients were at least 4 weeks after the end of treatment. Therapeutic results were : 15 cures and 2 failures by relapse in 17 cystitis, 6 cures and 3 failures by relapse in 9 pyelonephritis, 4 cures in 4 prostatitis. General tolerance was excellent in all cases. Intramusculary injections were well tolerated with a 2 p. cent lidocain solution. Biological tolerance and particularly renal tolerance was good in all patients.
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy; D002439:Cefotaxime / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015310:Cefotiam; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D014552:Urinary Tract Infections / Q000188:drug therapy*
D015310:Cefotiam; D002439:Cefotaxime
Evaluation clinique du céfotiam dans les infections urinaires de l'adulte.